论文部分内容阅读
目的:探讨枯草杆菌二联活菌对治疗亚临床肝性脑病的临床疗效和安全性。方法:80例亚临床肝性脑病患者随机分为枯草杆菌二联活菌(美常安)(n=40)和空白对照组(n=40),疗程60d,检测血氨浓度和进行数字连接试验来评价临床疗效,观察不良反应以评价其安全性。结果:治疗组患者的血氨浓度和NCT结果明显低于治疗前,且与对照组比较,差异有显著性意义(P<0.01)。治疗期间未发生严重不良反应。结论:应用枯草杆菌二联活菌对亚临床肝性脑病进行治疗,其疗效高,临床疗效好,不良反应较少。
Objective: To investigate the clinical efficacy and safety of Bacillus subtilis bivalent viable bacteria in the treatment of subclinical hepatic encephalopathy. Methods: Eighty patients with subclinical hepatic encephalopathy were randomly divided into two groups: Bacillus subtilis Bacillus subtilis (n = 40) and blank control group (n = 40) for 60 days. Blood ammonia concentration was measured and digital connection test To evaluate the clinical efficacy, adverse reactions observed to evaluate its safety. Results: The serum ammonia concentration and NCT in the treatment group were significantly lower than those before treatment, and the difference was statistically significant (P <0.01). No serious adverse reactions occurred during treatment. Conclusion: The treatment of subclinical hepatic encephalopathy with B. subtilis viable biotics has high curative effect, good clinical curative effect and few adverse reactions.